NCT02174848View on ClinicalTrials.gov

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
DRUG

Deferiprone oral solution

Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day

Trial Locations (4)

20133

Foundation Neurological Institute C. Besta, Milan

80336

Klinikum der Universität München, Munich

94609

UCSF Benioff Children's Hospital Oakland, Oakland

NE1 3BZ

Newcastle University Institute of Human Genetics, Newcastle upon Tyne

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT02174848 - Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration | Biotech Hunter | Biotech Hunter